Qualcomm 3Q Profit Rises on Strong QCT Revenue Growth
By Victor Swezey
Qualcomm delivered higher profits in the third quarter on sales growth in its QCT semiconductor segment.
The chip maker on Wednesday posted a profit of $2.13 billion, or $1.88 a share for the quarter ended June 23, compared with $1.8 billion, or $1.60 a share, a year earlier.
Adjusted earnings per share were $2.33. Analysts polled by FactSet expected adjusted earnings of $2.25 per share.
Revenue rose to $9.39 billion from $8.45 billion, beating analyst expectations of $9.21 billion.
By segment, revenue for the company's QCT semiconductor business grew 12% to $8.07 billion. QCT develops integrated circuits and system software for mobile devices, automotive connectivity systems and internet of things. Revenue for mobile devices rose 12% as automotive spiked 87%, while internet of things fell 8%.
Revenue for the QTL licensing business grew 3% to $1.27 billion.
For the upcoming quarter, the company predicted revenue between $9.5 billion and $10.3 billion, with QCT revenue between $8.1 billion and $8.7 billion and QTL revenue between $1.35 billion and $1.55 billion. The company forecast fourth-quarter earnings per share between $2.38 and $2.58.
Write to Victor Swezey at victor.swezey@wsj.com; @vicswezey
(END) Dow Jones Newswires
July 31, 2024 16:51 ET (20:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk